Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tianjin COSYCHEM Technology

Request full access

A national high-tech enterprise integrating technical services

Binhai New Area, ChinaFounded 2010Biotech & Life Sciences

About Tianjin COSYCHEM Technology

Established in October 2010, Tianjin COSYCHEM Technology Co., Ltd. operates as a pivotal supplier of chemical raw materials for the life sciences sector. The company, founded by Song Yanmin, has strategically positioned itself within China's biopharmaceutical landscape. After more than a decade of technological development, COSYCHEM has built a comprehensive business model that encompasses specialized pharmaceutical intermediates, raw materials for diagnostic analytics, and components for nucleic acid drugs.

The firm functions as a Contract Development and Manufacturing Organization (CDMO), providing integrated services from research and development to production for life science enterprises. Its operations are centered around multiple technology platforms, including synthetic technology, gene therapy delivery, nucleic acid drug discovery, and in-vitro diagnostics (IVD) services. The company's revenue is generated through the sale of its products and its CRO and CDMO services. COSYCHEM serves a client base primarily composed of pharmaceutical and life science companies.

COSYCHEM's product portfolio is extensive, featuring core materials for both in-vitro diagnostics and nucleic acid therapeutics. Key offerings include a delivery system for small nucleic acid drugs, known as GALNAc, and the capability to produce phosphoramidite monomers in multi-kilogram quantities. The company has also developed a cationic lipid library to create LNP delivery systems for gene therapy applications. To bolster its research capabilities, the company has forged strategic partnerships, establishing a joint laboratory for nucleic acid drug innovation with Peking University Health Science Center and a genomic nucleic acid technology platform with Nankai University. These collaborations are intended to advance the downstream application of nucleic acid drugs and vaccines.

Financially, the company has demonstrated significant growth, securing over RMB 200 million in financing over three years and completing a Pre-B round exceeding CNY 100 million in May 2024. This capital is earmarked for the commercial expansion of its biological technology chemical raw materials and their applications in nucleic acid drugs and IVD. COSYCHEM holds over 50 independent intellectual property rights and has received numerous national-level recognitions, including being named a National High-tech Enterprise and a National Recognized "Little Giant" Enterprise.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC May 2024 $14M $55M Cohesive Energy Investment ↗
EARLY VC✓Equity / VC Sep 2022 $14M $55M Tianchuang Venture Capital · Binhai Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Tianjin COSYCHEM Technology website traffic

Latest recorded traffic for Tianjin COSYCHEM Technology is 440 monthly website visits, down 70.7% over the last three months.

Latest monthly visits440 3-month web change-70.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tianjin COSYCHEM Technology in the Binhai New Area ecosystem

Live from Dealroom

The Tianjin COSYCHEM Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Tianchuang Venture Capital
  • Binhai Capital
  • Cohesive Energy Investment
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Binhai New Area HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tianjin COSYCHEM Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tianjin COSYCHEM Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.